Cyclacel Pharmaceuticals, Inc. (CYCC) Bundle
A Brief History of Cyclacel Pharmaceuticals, Inc. (CYCC)
Company Overview
Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Berkeley Heights, New Jersey. Founded in 1997, the company focuses on developing innovative cancer therapies.
Financial Performance
| Fiscal Year | Revenue ($) | Net Loss ($) | Stock Price (NASDAQ) |
|---|---|---|---|
| 2022 | 4.1 million | 22.4 million | 0.35 |
| 2023 | 3.9 million | 19.6 million | 0.22 |
Key Research Programs
- Fadraciclib (CDK inhibitor)
- CYC140 (polo-like kinase inhibitor)
- Ongoing clinical trials in hematologic and solid tumor cancers
Clinical Development Status
As of 2024, Cyclacel continues Phase 1/2 clinical trials for fadraciclib in various cancer indications.
Nasdaq Listing Details
Ticker Symbol: CYCC
Market Capitalization: Approximately 15.2 million USD
Corporate Leadership
Spiro Rombotis serves as President and CEO.
Who Owns Cyclacel Pharmaceuticals, Inc. (CYCC)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| Renaissance Technologies LLC | 303,529 | 2.44% |
| Millennium Management LLC | 258,200 | 2.08% |
| Citadel Advisors LLC | 172,526 | 1.39% |
Insider Ownership
- Spiro Rombotis (President and CEO): 126,600 shares
- Paul McBarron (CFO): 45,300 shares
- Daniel Passeri (Former Chairman): 92,500 shares
Ownership Structure
Public Float: 12,424,518 shares as of December 31, 2023
Total Outstanding Shares: 14,233,415 shares
Institutional Ownership Percentage
Total institutional ownership: 14.72% as of Q4 2023
Cyclacel Pharmaceuticals, Inc. (CYCC) Mission Statement
Corporate Overview
Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing cell cycle-based therapies for cancer and other serious diseases.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Market Capitalization | $14.6 million |
| Total Revenue | $1.2 million |
| Net Loss | $16.4 million |
| Cash and Cash Equivalents | $8.3 million |
Key Research Areas
- Cell cycle inhibitor therapeutics
- Cancer treatment development
- Precision medicine approaches
Research Pipeline
| Drug Candidate | Development Stage | Target Indication |
|---|---|---|
| Fadraciclib | Phase 2 Clinical Trials | Advanced Solid Tumors |
| Canfosfamide | Investigational Stage | Lung Cancer |
Strategic Focus
Develop innovative cell cycle-targeted therapies for patients with unmet medical needs.
Nasdaq Listing Details
| Stock Symbol | Exchange | Trading Price Range (2024) |
|---|---|---|
| CYCC | Nasdaq | $0.50 - $1.20 |
How Cyclacel Pharmaceuticals, Inc. (CYCC) Works
Company Overview
Cyclacel Pharmaceuticals, Inc. (CYCC) is a biopharmaceutical company focused on developing cell cycle-targeted therapies for cancer and other serious diseases.
Financial Performance
| Financial Metric | Amount (2023) |
|---|---|
| Total Revenue | $3.4 million |
| Net Loss | ($25.6 million) |
| Cash and Cash Equivalents | $18.7 million |
| Research and Development Expenses | $16.2 million |
Key Product Pipeline
- Fadraciclib (CYC065): CDK inhibitor for solid tumors
- Oral Sapacitabine: Treatment for acute myeloid leukemia
- CYC140: PLK inhibitor in preclinical development
Research Focus Areas
Cyclacel concentrates on cell cycle-targeted therapies with primary emphasis on oncology and hematology.
Clinical Trials Status
| Drug | Current Phase | Indication |
|---|---|---|
| Fadraciclib | Phase 1/2 | Advanced solid tumors |
| Sapacitabine | Phase 2 | Acute myeloid leukemia |
Corporate Information
- NASDAQ Ticker: CYCC
- Headquarters: Berkeley Heights, New Jersey
- Employees: Approximately 35
How Cyclacel Pharmaceuticals, Inc. (CYCC) Makes Money
Revenue Streams
Cyclacel Pharmaceuticals, Inc. generates revenue primarily through:
- Research and development of pharmaceutical products
- Potential licensing agreements
- Grant funding
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $4.1 million |
| Net Loss | $23.4 million |
| Research and Development Expenses | $14.2 million |
| Cash and Cash Equivalents | $22.6 million |
Key Product Portfolio
Primary Focus Areas:
- Oncology therapeutics
- Cell cycle and DNA damage response inhibitors
Funding Strategy
Cyclacel relies on:
- Public equity offerings
- Venture capital investments
- Government research grants
Stock Performance
| Stock Metric | 2024 Value |
|---|---|
| Stock Price (CYCC) | $0.38 per share |
| Market Capitalization | $15.2 million |
Cyclacel Pharmaceuticals, Inc. (CYCC) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.